How Smart Investors Look at Healthpeak Properties (PEAK).

By Kim Brooks • Thursday, November 03 12:00 • Permanent Link

Healthpeak Properties logged a 2.0% change during today's afternoon session, and is now trading at a price of $24.11 per share. The S&P 500 index moved -0.5% and the Dow Industrial Average posted a -1.4% change. PEAK's trading volume is 4,010,234 compared to the stock's average volume of 4,209,370.

Healthpeak Properties trades -19.8% away from its average analyst target price of $30.07 per share. The 15 analysts following the stock have set target prices ranging from $23 to $38, and on average have given Healthpeak Properties a rating of buy.

Below are some factors that could be affecting the stocks's performance and analyst recommendation:

Healthpeak Properties has moved -31.0% over the last year, and the S&P 500 logged a change of -19.7%
Based on its trailing earning per share of 0.4, Healthpeak Properties has a trailing 12 month Price to Earnings (P/E) ratio of 60.3 while the S&P 500 average is 15.97
PEAK has a forward P/E ratio is 53.6 based on its forward 12 month price to earnings (Eps) is $0.45 per share
The company has a price to earnings growth (PEG) ratio of -2.4 -- a number near or below 1 signifying that Healthpeak Properties is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 2.1 compared to its sector average of 2.39

Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Based in Denver, the company has 196 full time employees and a market cap of $13,011,995,648. Healthpeak Properties currently returns an annual dividend yield of 5.1%.

If you would like more in-depth discussions of stocks such as Healthpeak Properties, subscribe to our free newsletter!

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.